Penn Capital Management Company LLC Makes New $800,000 Investment in Nurix Therapeutics, Inc. $NRIX

Penn Capital Management Company LLC acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 32,983 shares of the company’s stock, valued at approximately $800,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Larson Financial Group LLC lifted its position in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after acquiring an additional 1,190 shares during the period. California State Teachers Retirement System increased its holdings in shares of Nurix Therapeutics by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock valued at $1,290,000 after purchasing an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management purchased a new stake in shares of Nurix Therapeutics during the fourth quarter worth approximately $31,000. Royal Bank of Canada raised its stake in shares of Nurix Therapeutics by 17.6% during the fourth quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after purchasing an additional 1,623 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in shares of Nurix Therapeutics by 8.2% during the fourth quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after purchasing an additional 1,674 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NRIX shares. Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Mizuho lifted their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Stifel Nicolaus boosted their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Royal Bank Of Canada increased their target price on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a research note on Monday, August 10th. Finally, UBS Group raised their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.21.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the transaction, the insider directly owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. The trade was a 4.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,314 shares of company stock valued at $589,361 over the last ninety days. 6.70% of the stock is currently owned by company insiders.

Nurix Therapeutics Trading Down 2.5%

Shares of NRIX opened at $26.21 on Friday. The firm’s 50-day moving average is $24.37 and its two-hundred day moving average is $18.99. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $28.23. The firm has a market capitalization of $2.72 billion, a P/E ratio of -7.60 and a beta of 1.79.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. Analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.